These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30015487)

  • 21. Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor.
    Chauhan J; Yoshioka M; Pogash S; Strovel JW; Fletcher S
    Bioorg Med Chem Lett; 2023 Apr; 86():129220. PubMed ID: 36905966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural variation of protein-ligand complexes of the first bromodomain of BRD4.
    Guest EE; Pickett SD; Hirst JD
    Org Biomol Chem; 2021 Jun; 19(25):5632-5641. PubMed ID: 34105560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
    Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
    Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors.
    Qiao XP; Wang XT; Wang S; Mu HX; Wang QS; Chen SW
    Bioorg Med Chem; 2024 May; 106():117752. PubMed ID: 38749341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.
    Jiang W; Hou Q; Xu H; Yang K; Wang X; Zhang K; Zeng Y; Li W; Wang B; Luo G; Zhao X; Shen H; Xu Y; Wu X
    J Med Chem; 2024 Jan; 67(2):1513-1532. PubMed ID: 38175809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
    Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
    J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
    Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
    Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.